Featured Research

from universities, journals, and other organizations

Beta-blocker associated with better outcomes in treatment of infantile vascular tumors

Date:
August 25, 2011
Source:
JAMA and Archives Journals
Summary:
Compared with oral corticosteroids, use of the beta-blocker propranolol for treatment of infantile hemangiomas was associated with higher rates of lesion clearance, fewer adverse effects, fewer surgical interventions after treatment, and lowers cost, according to a new report.

Compared with oral corticosteroids, use of the beta-blocker propranolol for treatment of infantile hemangiomas (IHs) was associated with higher rates of lesion clearance, fewer adverse effects, fewer surgical interventions after treatment, and lowers cost, according to a report published Online First by Archives of Dermatology, one of the JAMA/Archives journals.

Related Articles


A common type of vascular tumor, IH tends to grow rapidly during the first three to 12 months of age, and then slowly and spontaneously regress from three to seven years of age, according to background information in the study. However, this regression may not completely improve the patient's appearance. Further, when IH is untreated, patients may experience ulceration, scarring, recurrent bleeding and impairment of vision, hearing, feeding and defecation. In complicated cases, patients may have heart problems, structural abnormalities, cosmetic disfigurement or psychosocial problems. "Therefore, IHs often require systemic, surgical and/or laser treatment to avoid these adverse effects," write the authors. In most cases, corticosteroids are used to treat the disorder, with oral prednisolone the most common choice. Since 2008, studies have suggested that propranolol (a beta blocker drug used for heart and circulatory problems) may also help treat IH.

Cynthia J. Price, M.D., formerly of the Miller School of Medicine, University of Miami, and colleagues sought to evaluate the use of propranolol in patients with IH but with no cardiac abnormalities, and to gather information about optimal length of treatment, associated adverse effects and relapses when treatment ends. Between February 2005 and October 2010, they conducted a multicenter, retrospective review of the medical charts of 110 patients with IHs. Researchers used photographs and clinical examination results to divide patients into two groups: those whose IH was cleared by 75 percent or more (defined as a reduction of at least 75 percent in the tumor's volume) and those whose tumor clearance was less than 75 percent.

On average, treatment with propranolol lasted for 7.9 months and treatment with oral corticosteroids lasted 5.2 months. Of the 68 patients who received propranolol, 56 (82 percent) had tumor clearance of 75 percent or more, compared with 12 (29 percent) of 42 patients who received oral corticosteroids. Adverse events occurred in three patients receiving propranolol and all 42 patients receiving corticosteroids. In patients who received propranolol, relapse occurred after treatment ended, but improvement was noticed after another round of treatment. Eight patients (12 percent) in the propranolol group and 12 patients (29 percent) in the corticosteroid group needed further surgery. Overall, the average per-patient costs of treatment were $205.32 and $416.00 in the propranolol and oral prednisolone groups, respectively.

"In conclusion, our study showed that propranolol therapy was more effective in lesion clearance, required fewer surgical referrals after treatment and demonstrated superior tolerance, with minimal adverse effects," write the authors. "Propranolol proved to be safe in treating IH in our patients as no major adverse effects occurred. Also, propranolol therapy was more cost-effective, with a cost reduction of more than 50 percent per patient."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Cynthia J. Price; Carol Lattouf; Bertha Baum; Michael McLeod; Lawrence A. Schachner; Ana M. Duarte; Elizabeth Alvarez Connelly. Propranolol vs Corticosteroids for Infantile Hemangiomas: A Multicenter Retrospective Analysis. Archives of Dermatology, 2011; DOI: 10.1001/archdermatol.2011.203

Cite This Page:

JAMA and Archives Journals. "Beta-blocker associated with better outcomes in treatment of infantile vascular tumors." ScienceDaily. ScienceDaily, 25 August 2011. <www.sciencedaily.com/releases/2011/08/110815162243.htm>.
JAMA and Archives Journals. (2011, August 25). Beta-blocker associated with better outcomes in treatment of infantile vascular tumors. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2011/08/110815162243.htm
JAMA and Archives Journals. "Beta-blocker associated with better outcomes in treatment of infantile vascular tumors." ScienceDaily. www.sciencedaily.com/releases/2011/08/110815162243.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins